REDWOOD CITY, CALIFORNIA, USA, April 13, 2026
Revolution Medicines has announced positive topline results from its pivotal Phase 3 RASolute 302 clinical trial, demonstrating that daraxonrasib significantly improves overall survival and progression-free survival in patients with metastatic pancreatic ductal adenocarcinoma (PDAC). The study met all primary and key secondary endpoints, with results showing a median overall survival of 13.2 months compared to 6.7 months with standard chemotherapy, marking a clinically meaningful advancement in a disease with limited treatment options.
Phase 3 Trial Demonstrates Significant Survival Benefit
The global, randomized Phase 3 RASolute 302 study evaluated daraxonrasib, an oral RAS(ON) multi-selective inhibitor, in patients with previously treated metastatic PDAC. The results demonstrated a hazard ratio of 0.40 (p<0.0001) for overall survival, indicating a substantial reduction in the risk of death compared to chemotherapy. In addition to survival benefits, the therapy also achieved statistically significant improvements in progression-free survival, reinforcing its therapeutic potential. The trial enrolled patients with a wide range of RAS mutations, including G12 variants, as well as those without identified mutations, highlighting the drug’s broad applicability across pancreatic cancer subtypes.
Targeting RAS-Driven Cancers with Novel Mechanism
Daraxonrasib represents a new class of targeted therapies designed to inhibit RAS(ON) proteins, which are key drivers in more than 90% of pancreatic cancers. By blocking the interaction between RAS proteins and downstream signaling pathways, the drug aims to suppress tumor growth and progression. This innovative mechanism addresses a long-standing challenge in oncology, as RAS mutations have historically been considered difficult-to-target drivers of cancer. The therapy’s ability to demonstrate meaningful clinical outcomes in a Phase 3 setting underscores its potential to transform treatment strategies for RAS-driven malignancies, including pancreatic, lung, and colorectal cancers.
Advertisement
Regulatory Pathway and Clinical Impact
Based on these findings, Revolution Medicines plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration, as well as to other global regulatory authorities. The drug has already received Breakthrough Therapy Designation and Orphan Drug Designation from the FDA, further supporting its potential to address significant unmet medical needs. Importantly, daraxonrasib demonstrated a manageable safety profile with no new safety signals, which is critical for patients undergoing treatment for advanced cancers. Experts suggest that these results could be practice-changing, offering a new standard of care for patients with metastatic pancreatic cancer who have progressed on prior therapies.
Addressing a High-Unmet-Need Oncology Indication
Pancreatic cancer remains one of the most aggressive and lethal malignancies, with a five-year survival rate of approximately 3% for metastatic disease. Due to late diagnosis and resistance to conventional therapies, the majority of patients have limited treatment options. The introduction of daraxonrasib as a targeted therapy offers hope for improving survival outcomes and quality of life in this patient population. With its oral administration, targeted mechanism, and demonstrated efficacy, the drug has the potential to reshape the therapeutic landscape for pancreatic cancer and other RAS-driven tumors.
The Phase 3 RASolute 302 trial results highlight daraxonrasib as a promising next-generation targeted therapy capable of delivering significant survival benefits in metastatic pancreatic cancer. With strong clinical efficacy, a favorable safety profile, and ongoing plans for regulatory submission, the therapy represents a major advancement in oncology drug development. As the industry continues to focus on precision medicine and targeted therapies, daraxonrasib exemplifies the potential of innovative approaches to address historically difficult-to-treat cancers.
Source: Revolution Medicines press release
